Kevin W. Chamberlin, PharmD
Kevin W. Chamberlin, PharmD, is associate clinical professor and assistant department head, pharmacy practice, University of Connecticut School of Pharmacy, Storrs, Conn.
Key cogs in the management of Parkinson’s disease
Key cogs in the management of Parkinson’s disease
The goal of this activity is to assist pharmacists in managing difficult-to-treat symptoms of Parkinson’s disease.
FDA approves Epclusa (sofosbuvir/velpatasvir) for chronic hepatitis C infection
FDA approved EpclusaTM (sofosbuvir and velpatasvir, (SOF-VEL) for adults with chronic hepatitis C infection both with compensated cirrhosis or without cirrhosis as well as in combination with ribavirin for hepatitis C with decompensated cirrhosis.
Daclizumab approved for relapsing forms of multiple sclerosis
Daclizumab is the first subcutaneous injectable monoclonal antibody to be approved for the treatment of MS.
FDA approves brivaracetam for use in partial onset seizure treatment
Brivaracetam provides another adjunctive treatment option for partial onset seizures in patients with uncontrolled epilepsy.
FDA approves PAH treatment
Selexipag is a first-in-class oral treatment option to reduce progression and hospitalization for pulmonary arterial hypertension.
FDA approves sacubitril/valsartan to treat heart failure
For patients with heart failure, Entresto is the first treatment available that has been shown to decrease hospitalizations and reduce the risk of cardiovascular-related death.
FDA approves eluxadoline to treat IBS-D in adults
Few treatment options are available for irritable bowel syndrome with diarrhea. Eluxadoline acts on the nervous system to lessen bowel contraction.
FDA approves ceftazidime-avibactam to treat two complicated infections
The combination product is indicated to treat either complicated intra-abdominal infections, where it is used in combination with metronidazole, or complicated urinary tract infections in patients with few or no other treatment options.
FDA approves ferric citrate to treat hyperphosphatemia in dialysis patients
Auryxia, an iron-based phosphate binder, was approved September 5, 2014.
FDA approves extended-release oxycodone combo to deter abuse
An opioid analgesic with an abuse deterrent,Targiniq can deter but not entirely prevent abuse when snorted or injected.